LianBio Sponsored ADR (LIANY) AI Stock Analysis

• Market Cap: $5.86M
• Dividend Yield: N/A
• Average Volume (3M): 99.18K
• Price to Earnings (P/E): 0.1
• Beta (1Y): 0.09
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): 2.91
• Shares Outstanding: 108,062,640
• 10 Day Avg. Volume: 127,086
• 30 Day Avg. Volume: 99,177
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

LianBio's overall stock score is driven by its financial resilience due to strong cash reserves and equity position, but severely offset by its lack of revenue generation and persistent operational losses. The technical analysis indicates a bearish market sentiment, and the extremely low P/E ratio reflects market doubts about future profitability. The absence of significant earnings call data or corporate events means these factors do not influence the current score.

LianBio Sponsored ADR Business Overview & Revenue Model

Company Description

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

How the Company Makes Money

LianBio generates revenue primarily through strategic partnerships and collaboration agreements with global pharmaceutical and biotechnology companies. The company acquires the rights to develop and commercialize promising drug candidates in specific Asian markets, particularly China. LianBio earns money through milestone payments, royalties on sales, and profit-sharing from successfully commercialized products. These partnerships allow LianBio to leverage existing research and development efforts while focusing on navigating the regulatory and market landscape of its target regions.

LianBio Sponsored ADR Financial Statement Overview

Summary

LianBio's financial statements reflect a company with strong cash reserves and equity positions but facing significant challenges in revenue generation and profitability. While recent improvements in cash flow are positive, the lack of revenue and consistent operational losses highlight the need for strategic shifts to ensure long-term viability.

Income Statement

The company has consistently reported zero revenue over the past five years, with increasing net losses year-over-year. Although there is a significant improvement in net income in the latest year, it does not reflect operational revenue performance but rather other gains that improved net results. The EBIT and EBITDA margins remain negative, indicating operational and financial challenges.

Balance Sheet

LianBio has maintained a strong equity base with a high equity ratio due to low levels of debt, which indicates financial resilience. However, the absence of revenue generation could pose future risks if the company continues to rely on cash reserves without generating income.

Cash Flow

The company shows strong free cash flow and operating cash flow improvements in the latest year, indicating better cash management. However, the free cash flow growth rate is skewed due to prior negative cash flow, and the sustainability of this improvement remains uncertain without revenue.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-1.33M	-1.00M	-526.00K	-76.13K	0.00
EBITDA	312.91M	-109.49M	-195.52M	-134.90M	-24.38M
Net Income	311.14M	-110.16M	-196.56M	-139.84M	-24.37M
Balance Sheet
Total Assets	617.96M	319.96M	426.33M	279.29M	43.88M
Cash, Cash Equivalents and Short-Term Investments	567.37M	302.36M	383.24M	254.35M	43.30M
Total Debt	2.46M	4.34M	4.83M	1.88M	532.00K
Total Liabilities	36.77M	26.31M	39.01M	27.57M	3.69M
Stockholders Equity	581.20M	259.87M	353.55M	216.95M	39.18M
Cash Flow
Free Cash Flow	258.56M	-100.91M	-165.12M	-99.20M	-11.72M
Operating Cash Flow	258.94M	-99.07M	-164.17M	-98.31M	-11.72M
Investing Cash Flow	99.31M	-69.12M	-156.14M	-887.52K	0.00
Financing Cash Flow	1.78M	1.71M	313.69M	310.29M	55.09M

LianBio Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIANY, the sentiment is Neutral. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.05, and above the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 44.72 is Neutral, neither overbought nor oversold. The STOCH value of 8.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LIANY.

LianBio Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.95B	-0.38	-43.43%	2.22%	22.30%	-1.83%
LIANY	45 Neutral	$5.86M	0.14	53.53%	―	―	―
LGVN	44 Neutral	$16.47M	―	-134.50%	―	68.67%	85.44%
NNVC	42 Neutral	$23.95M	―	-99.84%	―	―	13.83%
CALC	39 Underperform	$43.03M	―	-209.36%	―	―	15.19%
TENX	36 Underperform	$27.35M	―	-56.12%	―	―	95.87%
CDIO	―	$6.54M	―	-97.67%	―	―	―